News

HDA Media And Political Bulletin – 12 August 2016

Medicines and Healthcare products Regulatory Agency: MHRA and making a success of Brexit

11 August, MHRA

Following the UK’s decision to leave the EU, the MHRA is working with the government to determine the best options and opportunities for the safe and effective regulation of both medicines and medical devices in the UK. The MHRA stresses that it remains a priority to continue to participate in the European regulatory procedures for medicines. The current preparations to implement proposed new Regulations for Medical Devices and in vitro diagnostic (IVD) devices is continuing despite the recent exit vote. The MHRA will continue to engage widely with stakeholders to fully understand and maximise the opportunities of Brexit.

Parliamentary Coverage

 

There is no parliamentary coverage today.

 

Full Coverage

 

Medicines and Healthcare products Regulatory Agency: MHRA and making a success of Brexit

11 August, MHRA

The Agency’s response to the outcome of the EU referendum.

Following the outcome of the EU referendum, the Medicines and Healthcare products Regulatory Agency (MHRA) is working closely with the Government to analyse the best options and opportunities available for the safe and effective regulation of medicines and medical devices in the UK.

While negotiations continue, the UK remains a full and active member of the EU, with all the rights and obligations of EU membership firmly in place. Working with our partners, stakeholders and customers, our focus remains: protecting health and improving lives.

Medicines regulation

Playing a full, active role in European regulatory procedures for medicines remains a priority. We contribute significantly in both the centralised and decentralised regulatory procedures, including new rapporteur and reference member state (RMS) appointments, and maintain our programmes for implementing EU legislation as required by our obligations as a Member State. We are also fully engaged in European and national scientific advice services and in delivering our EU inspection-related duties.

Devices regulation

Our role in regulating medical devices and in vitro diagnostic (IVD) devices remains integral. We oversee the essential work of the five UK Notified Bodies; together they are responsible for assessing the majority of devices currently placed on the EU market. Our preparations to implement proposed new Regulations for Medical Devices and IVDs continue.

Vigilance and market surveillance

We maintain our role in vigilance, market surveillance and taking direct action, where needed, to protect patients and public health, and we continue to co-ordinate with other Competent Authorities, across Europe and internationally, in these and other areas.

MHRA will be engaging widely with our stakeholders to fully understand and maximise the opportunities of Brexit.

HDA Media And Political Bulletin – 12 August 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?